4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa
EMERYVILLE, Calif.–(BUSINESS WIRE)–4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV…